Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. REOLYSIN The company focuses its research and development efforts on the development of REOLYSIN, its cancer therapeutic. The company’s cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. In tumour cells with this type of activation, the virus is cytotoxic but has no effect on the surrounding normal tissue. It is also possible to activate Ras through mutation of proteins that control its activity rather than through direct mutations of Ras itself. Business Strategy The company's business strategy is to develop REOLYSIN by continuing to progress the product through its clinical trial program assessing the safety and efficacy in human subjects; establish collaborations with experts to assist the company with scientific and clinical developments of this new pharmaceutical product; implement strategic alliances with selected pharmaceutical and biotechnology companies and selected laboratories, at a time and in a manner where such alliances might complement and expand its research and development efforts on the product and provide sales and marketing capabilities; utilize its broadening patent base and collaborator network as a mechanism to meet its strategic objectives; and develop relationships with companies that could be instrumental in assisting the company to access other innovative therapeutics. Regulations The company’s toll manufacturers are subject to periodic inspection by the United States Food and Drug Administration, the United States Drug Enforcement Administration (DEA), and other domestic and foreign authorities where applicable, and must comply with current Good Manufacturing Practices regulations. Patents and Trade Secrets The company has approximately 369 issued patents including 53 issued U.S. patents. History Oncolytics Biotech Inc. was founded in 1998. The company was incorporated in 1998 under the Business Corporations Act (Alberta).
oncolytics biotech inc
(ONCY:Consolidated Issue listed on NASDAQ Capital Market)
1167 Kensington Crescent, NW
Calgary, AB T2N 1X7
|No competitor information is available for ONCY.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.